Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma

Fukuoka,Kazuya; Kuribayashi,Kozo; Yamada,Shusai; Tamura,Kunihiro; Tabata,Chiharu; Nakano,Takashi

doi:10.3892/mco.2013.175

Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma

Authors:
- Kazuya Fukuoka
- Kozo Kuribayashi
- Shusai Yamada
- Kunihiro Tamura
- Chiharu Tabata
- Takashi Nakano
View Affiliations

Affiliations: Cancer Center, Hyogo College of Medicine, Nishinomiya, Hyogo 663‑8501, Japan, Department of Respiratory Medicine, Murakami Memorial Hospital, Asahi University, Gifu, Gifu 500‑8523, Japan, Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663‑8501, Japan
Published online on: September 2, 2013 https://doi.org/10.3892/mco.2013.175
Pages: 942-948

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant mesothelioma (MM) is a highly aggressive tumor associated with asbestos exposure. The identification of a marker specific for MM may be of considerable value for the early detection of this tumor and may be used in particular to screen groups with a history of asbestos exposure. The aim of this study was to evaluate serum soluble mesothelin‑related peptide (SMRP) levels as a diagnostic marker for MM and investigate whether its diagnostic value is enhanced by combination with other biomarkers. Serum SMRP levels were measured using a quantitative enzyme‑linked immunosorbent assay in 96 patients with MM, 55 patients with lung cancer and 39 individuals with a history of asbestos exposure. Receiver operating characteristic curves were constructed for performance evaluation. Stepwise logistic regression analysis was used to select marker combinations (MCs). Serum SMRP levels in patients with MM were significantly higher compared to those in the other groups (P<0.001). The sensitivity of SMRP levels in diagnosing MM was 56% and its specificity for MM vs. lung cancer and individuals with asbestos exposure was 87 and 92%, respectively. The area under the curve (AUC) was 0.76 [95% confidence interval (CI): 0.68‑0.83] for the differentiation between MM and lung cancer and 0.78 (95% CI: 0.71‑0.86) for the differentiation between MM and individuals with asbestos exposure. For the MC of presence of effusion, SMRP and carcinoembryonic antigen (CEA) levels, the AUC for the differentiation between MM and lung cancer (0.92; 95% CI: 0.88‑0.97) and the differentiation between MM and individuals with asbestos exposure (0.93; 95% CI: 0.87‑1.0) was significantly higher compared to that for SMRP alone (P=0.0001 and 0.0058, respectively). While the specificity of this MC was comparable to SMRP alone, its sensitivity was ~20% higher compared to that of SMRP alone. Therefore, combining SMRP and CEA improves the diagnostic performance of SMRP alone. A combination of serum biomarkers, including SMRP, may facilitate the non‑invasive diagnosis of MM.

View Figures

View References

1.	Tsao AS, Wistuba I, Roth JA and Kindler HL: Malignant pleural mesothelioma. J Clin Oncol. 27:2081–2090. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Sugarbaker DJ, Flores RM, Jaklitsch MT, et al: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 117:54–63. 1999. View Article : Google Scholar
3.	Krug LM, Pass HI, Rusch VW, et al: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 27:3007–3013. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Van Schil PE, Baas P, Gaafar R, et al: Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 36:1362–1369. 2010.PubMed/NCBI
5.	Bonfrer JM, Schouwink JH, Korse CM and Baas P: Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res. 17:2971–2973. 1997.PubMed/NCBI
6.	Schouwink J, Korse CM, Bonfrer JM, Hart AA and Baas P: Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer. 25:25–32. 1999. View Article : Google Scholar : PubMed/NCBI
7.	Paganuzzi M, Onetto M, Marroni P, et al: Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 119:1138–1142. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Hedman M, Arnberg H, Wernlund J, Riska H and Brodin O: Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res. 23:531–536. 2003.PubMed/NCBI
9.	Creaney J, van Bruggen I, Hof M, et al: Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest. 132:1239–1246. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Pass HI, Lott D, Lonardo F, et al: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 353:1564–1573. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Grigoriu BD, Scherpereel A, Devos P, et al: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 13:2928–2935. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Creaney J, Yeoman D, Demelker Y, et al: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol. 3:851–857. 2008. View Article : Google Scholar
13.	Rai AJ, Flores RM, Mathew A, et al: Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med. 48:271–278. 2010.
14.	Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ and Robinson BW: Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma - which is best? Lung Cancer. 74:55–60. 2011. View Article : Google Scholar : PubMed/NCBI
15.	Cristaudo A, Bonotti A, Simonini S, et al: Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol. 6:1587–1593. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Hassan R, Bera T and Pasten I: Mesothelin: a new target for immunotherapy. Clin Cancer Res. 10:3937–3942. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Ray M and Kindler HL: Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 136:888–896. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Hollevoet K, Nackaerts K, Thimpont J, et al: Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med. 181:620–625. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Cristaudo A, Bonotti A, Simonini S, Bruno R and Foddis R: Soluble markers for diagnosis of malignant pleural mesothelioma. Biomark Med. 5:261–273. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Hollevoet K, Reitsma JB, Creaney J, et al: Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 30:1541–1549. 2012. View Article : Google Scholar : PubMed/NCBI
21.	van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA and Moons KG: Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer. 104:1325–1333. 2011.PubMed/NCBI
22.	Schorge JO, Drake RD, Lee H, et al: Osteopontin as an adjunct to CA125 in determining recurrent ovarian cancer. Clin Cancer Res. 10:3474–3478. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Etzioni R, Falcon S, Gann PH, Kooperberg CL, Penson DF and Stampfer MJ: Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? Cancer Epidemiol Biomarkers Prev. 13:1640–1645. 2004.PubMed/NCBI
24.	Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC: World Health Organization Classification of Tumors, Pathology and Genetics. Tumours of the Lung, Pleura, Thymus, and Heart. IARC Press; Lyon: 2004
25.	Husain A, Colby T, Ordonez N, et al: Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 133:1317–1331. 2009.PubMed/NCBI
26.	DeLong ER, DeLong DM and Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristics curves: a nonparametric approach. Biometrics. 44:837–845. 1988. View Article : Google Scholar
27.	Beyer HL, Geschwindt RD, Glover CL, et al: Mesomark: a potential test for malignant pleural mesothelioma. Clin Chem. 53:666–672. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Weber DG, Taeger D, Pesch B, Kraus T, Brüning T and Johnen G: Soluble mesothelin-related peptides (SMRP)-high stability of a potential tumor marker for mesothelioma. Cancer Biomark. 3:287–292. 2007.PubMed/NCBI
29.	Scherpereel A, Grigoriu B, Conti M, et al: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 173:1155–1160. 2006. View Article : Google Scholar : PubMed/NCBI
30.	Cristaudo A, Foddis R, Vivaldi A, et al: Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 13:5076–5081. 2007. View Article : Google Scholar : PubMed/NCBI
31.	Amati M, Tomasetti M, Scartozzi M, et al: Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev. 17:163–170. 2008. View Article : Google Scholar : PubMed/NCBI
32.	Pass HI, Wali A, Tang N, et al: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 85:265–272. 2008. View Article : Google Scholar : PubMed/NCBI
33.	Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M and Muley T: Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol. 3:1317–1324. 2008. View Article : Google Scholar
34.	van den Heuvel MM, Korse CM, Bonfrer JM and Baas P: Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer. 59:350–354. 2008.PubMed/NCBI
35.	Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al: Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev. 18:646–650. 2009.
36.	Robinson BW, Creaney J, Lake R, et al: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 362:1612–1616. 2003. View Article : Google Scholar : PubMed/NCBI
37.	Ordonez NG: The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 27:1031–1051. 2003. View Article : Google Scholar : PubMed/NCBI
38.	Ordonez NG: Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 27:1418–1428. 2003. View Article : Google Scholar : PubMed/NCBI